Nu-Med Plus Selects Houlihan Advisors To Valuate Company
SALT LAKE CITY, UT--(Marketwired - April 05, 2017) - Nu-Med Plus, Inc. (
Nu-Med Plus being a research and development company has accumulated considerable technical know how, intellectual property, and developed multiple products. Houlihan Advisors has been secured with the intention of providing a current valuation of these assets. Mr. Jeff Robins, CEO of Nu-Med Plus, commented, "This valuation will allow us to confidently position the company with respect to financial markets and potential acquisition interests."
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more company information please visit www.nu-medplus.com.
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.